{
    "xml": "<topic id=\"PHP531\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/mercaptopurine\" basename=\"mercaptopurine\" title=\"MERCAPTOPURINE\">\n<title>MERCAPTOPURINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_510\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antimetabolites/mercaptopurine\">Mercaptopurine</xref>\n</p>\n<data name=\"vtmid\">1039008</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n<p outputclass=\"synonyms\">6-Mercaptopurine</p>\r\n</body>\n<topic id=\"PHP69068\" outputclass=\"indicationsAndDose\" rev=\"1.33\" parent=\"/drugs/mercaptopurine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe acute Crohn's disease</p>\n<p outputclass=\"therapeuticIndication\">Maintenance of remission of Crohn's disease</p>\n<p outputclass=\"therapeuticIndication\">Ulcerative colitis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8211;1.5&#8239;mg/kg daily, some patients may respond to lower doses.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Acute leukaemias</p>\n<p outputclass=\"therapeuticIndication\">Chronic myelioid leukaemia</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using tablets</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 2.5&#8239;mg/kg daily, adjusted according to response, alternatively initially 50&#8211;75&#8239;mg/m<sup>2</sup> daily, adjusted according to response.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By mouth using oral suspension</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 25&#8211;75&#8239;mg/m<sup>2</sup> daily, adjusted according to response.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>\n<i>Puri-Nethol</i>\n<tm tmtype=\"reg\"/> tablets and <i>Xaluprine</i>\n<tm tmtype=\"reg\"/> oral suspension are <b>not</b> bioequivalent, haematological monitoring is advised when switching formulations.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68976\" outputclass=\"unlicensedUse\" rev=\"1.21\" parent=\"/drugs/mercaptopurine\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Not licensed for use in severe ulcerative colitis and Crohn&#8217;s disease.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69112\" outputclass=\"importantSafetyInformation\" rev=\"1.8\" parent=\"/drugs/mercaptopurine\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69123\" outputclass=\"contraindications\" rev=\"1.9\" parent=\"/drugs/mercaptopurine\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Absent thiopurine methyltransferase activity</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69143\" outputclass=\"cautions\" rev=\"1.12\" parent=\"/drugs/mercaptopurine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Reduced thiopurine methyltransferase activity</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Thiopurine methyltransferase </p>\n<p>The enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69059\" outputclass=\"interactions\" rev=\"1.13\" parent=\"/drugs/mercaptopurine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (mercaptopurine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69000\" outputclass=\"sideEffects\" rev=\"1.22\" parent=\"/drugs/mercaptopurine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Pancreatitis</ph>; <ph outputclass=\"sideEffect\">transient oligospermia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Intestinal ulceration</ph>; <ph outputclass=\"sideEffect\">lymphoma</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">anorexia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">hepatotoxicity</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Gastro-intestinal side-effects</p>\n<p>Tioguanine has a lower incidence of gastrointestinal side-effects than mercaptopurine.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69135\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/mercaptopurine\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause.</p>\n<p>No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69053\" outputclass=\"pregnancy\" parent=\"/drugs/mercaptopurine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (teratogenic).</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69163\" outputclass=\"breastFeeding\" parent=\"/drugs/mercaptopurine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69082\" outputclass=\"hepaticImpairment\" parent=\"/drugs/mercaptopurine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>May need dose reduction.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69033\" outputclass=\"renalImpairment\" parent=\"/drugs/mercaptopurine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69021\" outputclass=\"preTreatmentScreening\" rev=\"1.12\" parent=\"/drugs/mercaptopurine\">\n<title>Pre-treatment screening</title>\n<body>\n<section>\n<sectiondiv>\n<p>Consider measuring thiopurine methyltransferase (TPMT) activity before starting mercaptopurine therapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68959\" outputclass=\"monitoringRequirements\" parent=\"/drugs/mercaptopurine\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor liver function.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59726\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.17\" parent=\"/drugs/mercaptopurine\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>\n<i>Puri-Nethol</i>\n<tm tmtype=\"reg\"/> tablets and <i>Xaluprine</i>\n<tm tmtype=\"reg\"/> oral suspension are <b>not</b> bioequivalent, haematological monitoring is advised when switching formulations.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Flavours of oral liquid formulations may include raspberry.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP531-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/mercaptopurine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension, tablet, capsule</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75152\" title=\"Tablet\" namespace=\"/drugs/mercaptopurine/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75228\" title=\"Oral suspension\" namespace=\"/drugs/mercaptopurine/oral-suspension\">Oral suspension</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78151\" namespace=\"/treatment-summaries/immune-response\" title=\"Immune response\" count=\"2\" rel=\"backlink\">Immune response</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78316\" namespace=\"/treatment-summaries/inflammatory-bowel-disease\" title=\"Inflammatory bowel disease\" count=\"5\" rel=\"backlink\">Inflammatory bowel disease</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78537\" namespace=\"/treatment-summaries/cytotoxic-drugs\" title=\"Cytotoxic drugs\" count=\"1\" rel=\"backlink\">Cytotoxic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_510\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antimetabolites/mercaptopurine\" title=\"Mercaptopurine\" count=\"1\" rel=\"link\">Mercaptopurine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75152\" namespace=\"/drugs/mercaptopurine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75228\" namespace=\"/drugs/mercaptopurine/oral-suspension\" title=\"Oral suspension\" count=\"1\" rel=\"link\">Oral suspension</xref>\n</links>\n</topic>",
    "id": "PHP531",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/mercaptopurine",
    "basename": "mercaptopurine",
    "title": "MERCAPTOPURINE",
    "interactants": [
        {
            "id": "bnf_int_510",
            "label": "Mercaptopurine"
        }
    ],
    "vtmid": "1039008",
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "6-Mercaptopurine"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Severe acute Crohn's disease",
                        "html": "Severe acute Crohn's disease"
                    },
                    {
                        "textContent": "Maintenance of remission of Crohn's disease",
                        "html": "Maintenance of remission of Crohn's disease"
                    },
                    {
                        "textContent": "Ulcerative colitis",
                        "html": "Ulcerative colitis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "1&#8211;1.5 mg/kg daily, some patients may respond to lower doses.",
                        "html": "<p>1&#8211;1.5&#8239;mg/kg daily, some patients may respond to lower doses.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Acute leukaemias",
                        "html": "Acute leukaemias"
                    },
                    {
                        "textContent": "Chronic myelioid leukaemia",
                        "html": "Chronic myelioid leukaemia"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using oral suspension"
                    ],
                    "textContent": "By mouth using oral suspension",
                    "html": "By mouth using oral suspension"
                },
                "adult": [
                    {
                        "textContent": "Initially 2.5 mg/kg daily, adjusted according to response, alternatively initially 50&#8211;75 mg/m2 daily, adjusted according to response.",
                        "html": "<p>Initially 2.5&#8239;mg/kg daily, adjusted according to response, alternatively initially 50&#8211;75&#8239;mg/m<sup>2</sup> daily, adjusted according to response.</p>"
                    },
                    {
                        "textContent": "Initially 25&#8211;75 mg/m2 daily, adjusted according to response.",
                        "html": "<p>Initially 25&#8211;75&#8239;mg/m<sup>2</sup> daily, adjusted according to response.</p>"
                    }
                ]
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "Puri-Nethol tablets and Xaluprine oral suspension are not bioequivalent, haematological monitoring is advised when switching formulations.",
                "html": "<p>\n<i>Puri-Nethol</i>\n<tm tmtype=\"reg\"/> tablets and <i>Xaluprine</i>\n<tm tmtype=\"reg\"/> oral suspension are <b>not</b> bioequivalent, haematological monitoring is advised when switching formulations.</p>"
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Not licensed for use in severe ulcerative colitis and Crohn&#8217;s disease.",
                "html": "<p>Not licensed for use in severe ulcerative colitis and Crohn&#8217;s disease.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity; staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Absent thiopurine methyltransferase activity",
                "html": "Absent thiopurine methyltransferase activity"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Reduced thiopurine methyltransferase activity",
                "html": "Reduced thiopurine methyltransferase activity"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Thiopurine methyltransferase",
                "textContent": "The enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.",
                "html": "<p>The enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (mercaptopurine).",
                "html": "<p>Appendix 1 (mercaptopurine).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Pancreatitis",
                        "html": "Pancreatitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "transient oligospermia",
                        "html": "transient oligospermia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Intestinal ulceration",
                        "html": "Intestinal ulceration",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "lymphoma",
                        "html": "lymphoma",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "anorexia",
                        "html": "anorexia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatotoxicity",
                        "html": "hepatotoxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Gastro-intestinal side-effects",
                "textContent": "Tioguanine has a lower incidence of gastrointestinal side-effects than mercaptopurine.",
                "html": "<p>Tioguanine has a lower incidence of gastrointestinal side-effects than mercaptopurine.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause.\n\nNo increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause.</p><p>No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (teratogenic).\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid (teratogenic).</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "May need dose reduction.",
                "html": "<p>May need dose reduction.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose.",
                "html": "<p>Reduce dose.</p>"
            }
        ]
    },
    "preTreatmentScreening": {
        "preTreatmentScreening": [
            {
                "type": "preTreatmentScreening",
                "textContent": "Consider measuring thiopurine methyltransferase (TPMT) activity before starting mercaptopurine therapy.",
                "html": "<p>Consider measuring thiopurine methyltransferase (TPMT) activity before starting mercaptopurine therapy.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor liver function.",
                "html": "<p>Monitor liver function.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Puri-Nethol tablets and Xaluprine oral suspension are not bioequivalent, haematological monitoring is advised when switching formulations.",
                "html": "<p>\n<i>Puri-Nethol</i>\n<tm tmtype=\"reg\"/> tablets and <i>Xaluprine</i>\n<tm tmtype=\"reg\"/> oral suspension are <b>not</b> bioequivalent, haematological monitoring is advised when switching formulations.</p>"
            },
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Flavours of oral liquid formulations may include raspberry.",
                "html": "<p>Flavours of oral liquid formulations may include raspberry.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension",
                "tablet",
                "capsule"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75152",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75228",
                "label": "Oral suspension",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP78151",
                "label": "Immune response",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78316",
                "label": "Inflammatory bowel disease",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78537",
                "label": "Cytotoxic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_510",
                "label": "Mercaptopurine",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75152",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75228",
                "label": "Oral suspension",
                "type": "medicinalForm"
            }
        ]
    }
}